Compass Pathways reports Q2 2026 net loss of $253.8M; COMP360 NDA on track for Q4

COMPASS Pathways plc

2026-Q2 EPS reported -$1.33

Q2 net loss $253.8M ($1.88/share) vs $38.4M in Q2 2025; increase from non-cash warrant adjustments.
Cash and equivalents $433.3M as of June 30, 2026, up from $149.6M at Dec 31, 2025; expected to fund operations into 2028.
Rolling NDA submission for COMP360 in TRD underway; final submission expected Q4 2026; commercial launch targeted H1 2027.
Positive Phase 3 data showed rapid onset and durable benefit through 6 months; COMP360 expected to be blockbuster if approved.
R&D expenses $29.2M in Q2 2026 vs $30.3M in Q2 2025; G&A increased to $23.2M from $12.6M due to commercial prep.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.